discovered that LRRC15+ myCAFs in pancreatic cancer are activated by TGF‐β.[62] Yann Kieffer found that LAMP5+ myCAF in breast cancer is mainly activated by TGF‐β,[63] whereas the TME subtype that specifically accepts TGF‐β in CRC has not been fully clarified, which limits antitumor therapy via TGF‐β targeting. This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.